Hansoh Pharmaceutical (03692.HK) Rises Nearly 6% as Class 1 New Drug HS-10529 Granted IND Approval for KRAS G12D-Mutant Advanced Solid Tumors

According to the Zhisheng Finance APP, Hansoh Pharma (03692) rose nearly 6%. As of the time of writing, it increased by 5.88%, trading at HK$23.4, with a turnover of HK$134 million.

In terms of news, according to the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration and publicly available information, from April 14 to April 19, ten Class 1 innovative drugs received Investigational New Drug (IND) approval for clinical trials in China for the first time. These products cover various types such as small molecules, antibody-drug conjugates (ADCs), gene therapies, and cell therapies. The proposed indications include advanced solid tumors, type 1 diabetes, spinal cord injuries, as well as Duchenne muscular dystrophy (DMD) and paroxysmal nocturnal hemoglobinuria.

Among them, Hansoh Pharma's Class 1 new drug HS-10529 tablets have been approved for clinical trials, intended for the treatment of advanced solid tumors (pancreatic cancer, colorectal cancer, non-small cell lung cancer, etc.) with KRAS G12D mutations. According to the introduction in Hansoh Pharma's press release, this is a small molecule inhibitor targeting KRAS G12D developed by the company, featuring high selectivity. Preclinical efficacy trials have shown that HS-10529 exhibits good preclinical efficacy, pharmacokinetic properties, and safety.

In addition, Hansoh Pharma has two other Class 1 new drugs that have been approved for IND in China for the first time, but the specific mechanisms of action of these products cannot be found through public channels. They are: HS-20118 tablets, intended for the development to treat moderate to severe plaque psoriasis; and HS-10542 capsules, intended for the development to treat paroxysmal nocturnal hemoglobinuria.